gatifloxacin has been researched along with Cardiovascular Diseases in 5 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xia, J | 1 |
| Zhao, Y | 1 |
| Chen, HH | 1 |
| Wang, J | 1 |
| Muhlestein, JB | 1 |
| Cannon, CP | 1 |
| Braunwald, E | 1 |
| McCabe, CH | 1 |
| Grayston, JT | 1 |
| Muhlestein, B | 1 |
| Giugliano, RP | 1 |
| Cairns, R | 1 |
| Skene, AM | 1 |
| Anderson, JL | 1 |
| Frothingham, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000617] | Phase 3 | 0 participants | Interventional | 1998-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for gatifloxacin and Cardiovascular Diseases
| Article | Year |
|---|---|
Antibiotic treatment of atherosclerosis.
Topics: Animals; Anti-Bacterial Agents; Arteriosclerosis; Azithromycin; C-Reactive Protein; Cardiovascular D | 2003 |
1 trial available for gatifloxacin and Cardiovascular Diseases
| Article | Year |
|---|---|
Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome.
Topics: Aged; Angina, Unstable; Anti-Bacterial Agents; Cardiovascular Diseases; Chlamydophila Infections; Ch | 2005 |
3 other studies available for gatifloxacin and Cardiovascular Diseases
| Article | Year |
|---|---|
The correlation between gatifloxacin's acute adverse reaction and intravenous drip velocity.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cardiovascular Diseases; Drug Eruptions; Female; Fluoroqui | 2013 |
Infection, antibiotics, and atherothrombosis--end of the road or new beginnings?
Topics: Angina, Unstable; Anti-Bacterial Agents; Azithromycin; Cardiovascular Diseases; Chlamydophila Infect | 2005 |
Chlamydia pneumoniae and acute coronary syndrome.
Topics: Anti-Bacterial Agents; Cardiovascular Diseases; Cause of Death; Chlamydophila Infections; Chlamydoph | 2005 |